Revolutionary Organ Preservation Technology Unveiled at Hopkins Event

X-Therma Presents Innovative Organ Preservation Technology

On June 11, 2025, X-Therma Inc. showcased its cutting-edge organ preservation technology at the esteemed "Hopkins on the Hill" event organized by Johns Hopkins University in Washington, D.C. This annual gathering highlights significant federally funded research from various sectors, including healthcare technology, artificial intelligence, and organ transplantation.

X-Therma's next-generation organ preservation system, known as XT-ViVo® TimeSeal®, was spotlighted among the top 20 groundbreaking technologies presented at the event. This revolutionary system facilitates ice-free organ preservation at subzero temperatures, substantially enhancing the feasibility of organ transplantations, minimizing rejection risks, and easing the crucial processes of transplantation surgeries and donations.

The impressive presentation was led by prominent figures from Johns Hopkins University, including Dr. Gerald Brandacher, Dr. Byoung Chol Oh, and Amanda Loftin, PhD, DVM. With attendance from U.S. Senate members, XT-ViVo® and TimeSeal® were designated as one of 16 life-saving innovations, further solidifying X-Therma’s reputation as a pioneer in ice-free organ preservation techniques.

Transformative Technology in Organ Preservation

The XT-ViVo® system epitomizes innovation in the realm of organ preservation. By utilizing X-Therma's proprietary antifreeze peptoids derived from Arctic organisms, the technology effectively wards off ice crystal formation during the preservation process. Its integration with the smart transporter, TimeSeal®, allows organs to be preserved not just for hours, but for several days in ice-free conditions at subzero temperatures. This development represents a major breakthrough, addressing one of the primary obstacles in organ transplantation: the limited timeframe for transporting organs from donors to patients in dire need.

Dr. Gerald Brandacher expressed enthusiasm about the positive reception of this innovative technology at Capitol Hill. "It was uplifting to witness such keen interest and hear encouraging feedback regarding XT-ViVo and TimeSeal for subzero organ storage," he noted.

Commitment to Transforming Organ Transplantation

X-Therma's involvement in the Hopkins event highlights the company’s ambition to enhance organ preservation and transplantation methods. This venture is supported by the NIH Small Business Innovation Research (SBIR) Direct-to-Phase II program, underlining the importance of federally backed research in fostering lifesaving innovations in healthcare.

Xiaoxi Wei, Co-Founder and CEO of X-Therma, mentioned, “The remarkable response from Capitol Hill underscores how collaboration fueled by scientific inquiry can swiftly revolutionize transplant care—from groundbreaking discoveries to practical applications at the patient’s bedside. We are grateful for our enduring partnership with Dr. Brandacher and Dr. Oh at Johns Hopkins.”

X-Therma’s pioneering achievements include the world’s first successful transatlantic transportation of pig kidneys preserved for periods extending between 48 to 72 hours using the FDA-approved XT-ViVo® and TimeSeal®. Designed for compatibility with commercial aircraft, TimeSeal® ensures meticulous monitoring of essential storage elements—temperature, duration, and location—without reliance on external energy supplies.

The Future of Organ Preservation

X-Therma's innovations set the stage for a future where organ preservation times are significantly extended, potentially allowing global sharing of organs to meet demands once domestic needs are satisfied. X-Therma Inc., based in Hercules, California, is at the forefront of biotechnology, dedicated to evolving regenerative medicine and organ transplant practices. The firm has developed non-toxic, biocompatible antifreeze molecules that address issues of ice crystal formation during organ preservation.

Bolstered by a recent oversubscribed Series B funding of $22.4 million and a growing foothold in Austria, X-Therma is gearing up for accelerated commercialization and clinical advancements. The FDA has also granted Breakthrough Device designation to its XT-ViVo® and TimeSeal® systems for kidney preservation practices extending up to 120 hours, promising a transformative impact on the organ transplantation sector and hope for countless patients awaiting essential transplants.

As X-Therma continues to forge ahead, its participation at the Hopkins on the Hill event marks a pivotal moment in the organization's mission to redefine organ transplantation and meet the ever-increasing needs for viable organs in the healthcare landscape globally.

For further details about X-Therma and its revolutionary technologies, please visit www.x-therma.com.